The NMDA agonist D-cycloserine facilitates fear memory consolidation in humans.
about
NMDA receptors and fear extinction: implications for cognitive behavioral therapyEmotional processing in anterior cingulate and medial prefrontal cortexNMDA receptor agonists reverse impaired psychomotor and cognitive functions associated with hippocampal Hbegf-deficiency in miceAn Overview of Translationally Informed Treatments for Posttraumatic Stress Disorder: Animal Models of Pavlovian Fear Conditioning to Human Clinical Trialsd-Cycloserine augmentation of cognitive remediation in schizophrenia.Fear conditioning, synaptic plasticity and the amygdala: implications for posttraumatic stress disorderPharmacological enhancement of fear reduction: preclinical models.D-cycloserine facilitation of fear extinction and exposure-based therapy might rely on lower-level, automatic mechanisms.Effects of pharmacological manipulations of NMDA-receptors on deliberation in the Multiple-T task.Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder.Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions.A stable sparse fear memory trace in human amygdalaD-cycloserine facilitates extinction of cocaine self-administration in C57 mice.Effects of sleep on memory for conditioned fear and fear extinction.A controlled trial of the adjunct use of D-cycloserine to facilitate cognitive behavioral therapy outcomes in a cocaine-dependent populationNeuronal correlates of extinction learning are modulated by sex hormonesAugmenting NMDA receptor signaling boosts experience-dependent neuroplasticity in the adult human brainMechanisms of memory enhancementOne-year-old fear memories rapidly activate human fusiform gyrus.A high-throughput clinical assay for testing drug facilitation of exposure therapy.Sleep-dependent declarative memory consolidation--unaffected after blocking NMDA or AMPA receptors but enhanced by NMDA coagonist D-cycloserine.The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders.A bout of voluntary running enhances context conditioned fear, its extinction, and its reconsolidationPotentiation of GluN2C/D NMDA receptor subtypes in the amygdala facilitates the retention of fear and extinction learning in mice.D-cycloserine in Schizophrenia: New Strategies for Improving Clinical Outcomes by Enhancing Plasticity.A Meta-Analysis of D-Cycloserine in Exposure-Based Treatment: Moderators of Treatment Efficacy, Response, and Diagnostic Remission.The role of working memory and declarative memory in trace conditioning.The NMDA receptor partial agonist d-cycloserine does not enhance motor learningD-cycloserine potentiates the reconsolidation of cocaine-associated memories.Long-term expression of human contextual fear and extinction memories involves amygdala, hippocampus and ventromedial prefrontal cortex: a reinstatement study in two independent samples.An fMRI study examining effects of acute D-cycloserine during symptom provocation in spider phobia.A neuropeptide S receptor variant associated with overinterpretation of fear reactions: a potential neurogenetic basis for catastrophizing.No evidence for enhanced extinction memory consolidation through noradrenergic reuptake inhibition-delayed memory test and reinstatement in human fMRI.Associative learning versus fear habituation as predictors of long-term extinction retention.A pragmatic comparison of noise burst and electric shock unconditioned stimuli for fear conditioning research with many trials.Neural signatures of human fear conditioning: an updated and extended meta-analysis of fMRI studies.Facilitation of fear extinction by the 5-HT(1A) receptor agonist tandospirone: possible involvement of dopaminergic modulation.Effect of D-cycloserine and valproic acid on the extinction of reinstated fear-conditioned responses and habituation of fear conditioning in healthy humans: a randomized controlled trial.A randomised trial of the effect of the glycine reuptake inhibitor Org 25935 on cognitive performance in healthy male volunteers.Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy.
P2860
Q24604822-A0B5D4C5-6FF8-4738-9EC7-320FC7047AABQ24629806-D6C56713-8E3C-4486-AF86-2D04D5BA2DB6Q27300850-7B455986-BA7B-436E-8E5B-534BC36309F7Q30375098-96FC46EA-4F81-4C6C-94D9-51993C17D2E5Q30404599-697E4FB8-4131-4CD2-9779-E071DEDC20BBQ30459672-AC55DEF3-DF43-45B9-868A-1BB2755B323BQ30462825-68D50A91-0903-4EB9-A35A-A3AD70FE503CQ30479274-B5E6179F-86CA-4449-B93E-C769B10E0675Q30499450-48FCCBD8-4B2E-41F5-AD27-EC862C3C719BQ34017493-ACA2A697-3F6E-414C-90AC-16E91A028723Q34500045-9B43F2BF-4088-4D36-9893-69E474F04B2FQ35135154-086ACD40-45EF-4808-B7C9-BE3351E7945EQ35329570-AE6A1991-FEDD-4D4D-B112-41F38827DA34Q35802051-F7CAAF4D-0443-4EC0-ABBB-DAE8D4D98487Q36005220-CF81381D-93D8-40DB-A747-E5175C9E51B6Q36330169-37EC5011-46B9-4E2E-B1CD-0EFD2AF453DEQ36394299-7A3E1B71-413E-4267-9797-0F08B2591C08Q36481055-B4EA8935-7EB5-4602-AEAA-9DE607BBA40AQ36521849-52331B2D-2F86-499F-9203-DAC0ECBB70C2Q36977590-8738A7E3-D0F6-4B4D-A7E6-E7080CBD5B7EQ37309767-EB527F74-B340-4126-BFEB-77704EE05F85Q37318862-A4E65595-D87E-4A92-AFFC-68D023E7F818Q37491511-5F6D8B32-B684-4744-84A2-E521E08D2FF5Q37491564-88A808BE-85B4-46A9-90DB-F9A5DB7ABEFDQ38750121-84F20790-4772-4835-ADC0-2CCF8CAAEF29Q38851779-83F6BE49-C8F2-413A-A350-7F9A714CB681Q38898260-364F9B6A-F450-4126-853C-1794664F7E0BQ41476154-C4B6BCE2-1C6A-4A4B-8AF3-40014A30C9AFQ41970731-DCE5775E-AC1B-4F4F-A740-4FAA38AF21EBQ43045811-AAD643A0-005B-4A04-8CDF-2CD530554F9FQ43186100-88665A26-1EC6-4A6F-AB2C-80BD0FC44491Q43582104-D5AC2BB2-BD68-4299-A061-3EE2C03E4DF9Q44773470-9D52E82D-52A4-42FD-851A-BA3ADBFDB184Q46469944-D5625CD0-A24D-4D5D-876A-4551B1FD47F2Q47421633-40B73A01-27F6-456B-9017-0923318B1DA5Q47678357-3FA13EA2-8521-43C6-8837-1AF6E6850D67Q48295554-C4A6D7CF-FCA7-4161-A031-5A975D6B9C7FQ50628293-DBD5CD2A-FCBA-42A5-ACDE-ABAC0A21FC1AQ50695785-BD967FDA-70F5-4870-98D7-A5E3F8EA47CBQ50741478-40E168A5-5EBD-4109-9F07-4360CD442861
P2860
The NMDA agonist D-cycloserine facilitates fear memory consolidation in humans.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The NMDA agonist D-cycloserine facilitates fear memory consolidation in humans.
@en
The NMDA agonist D-cycloserine facilitates fear memory consolidation in humans.
@nl
type
label
The NMDA agonist D-cycloserine facilitates fear memory consolidation in humans.
@en
The NMDA agonist D-cycloserine facilitates fear memory consolidation in humans.
@nl
prefLabel
The NMDA agonist D-cycloserine facilitates fear memory consolidation in humans.
@en
The NMDA agonist D-cycloserine facilitates fear memory consolidation in humans.
@nl
P2093
P2860
P356
P1433
P1476
The NMDA agonist D-cycloserine facilitates fear memory consolidation in humans.
@en
P2093
Beatrice Holt
Christian Büchel
Predrag Petrovic
Raffael Kalisch
Stefan Klöppel
P2860
P304
P356
10.1093/CERCOR/BHN076
P577
2008-05-13T00:00:00Z